
During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.